Want to see HK:3613 full AI Analyst Report?
3613 Stock Chart & Stats
HK$6.54
HK$0.07(1.05%)
At close: 4:00 PM EDT
HK$6.54
HK$0.07(1.05%)
Day’s Range― - ―
52-Week RangeHK$5.49 - HK$9.50
Previous CloseN/A
Volume566.00K
Average Volume (3M)1.26M
Market Cap
HK$4.63B
Enterprise ValueHK$3.52K
Total Cash (Recent Filing)HK$2.21B
Total Debt (Recent Filing)HK$125.80M
Price to Earnings (P/E)10.0
Beta0.66
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.68%
Share Statistics
EPS (TTM)0.55
Shares Outstanding837,100,000
10 Day Avg. Volume1,622,706
30 Day Avg. Volume1,260,098
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)1.69
Price to Sales (P/S)4.68
P/FCF Ratio8.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.50Price Target Upside60.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.52
Revenue Forecast (FY)HK$1.58B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityThe company’s high gross and net margins indicate substantial earnings capacity from its TCM portfolio and brand-led sales model. Strong profitability can support product investment, distribution development, and resilience over the next several quarters, provided margins remain defensible.
Conservative Balance SheetMinimal leverage gives the company considerable financial flexibility and reduces exposure to interest costs or refinancing pressure. A conservatively financed balance sheet can help preserve investment capacity, support dividends, and absorb operating volatility without relying heavily on new borrowing.
Strong TTM Cash GenerationRecent cash generation closely tracks reported earnings, indicating that TTM profitability is converting into substantial operating and free cash flow. This supports internally funded growth, shareholder distributions, and ongoing business needs without requiring significant external financing.
Bears Say
Uneven Revenue GrowthThe recent rebound is encouraging, but declines in multiple annual periods show that top-line expansion has not been consistently steady. Uneven revenue performance can make channel planning and operating leverage less predictable, increasing reliance on continued recovery in demand.
Margin NormalizationAlthough current profitability remains strong, the lower net margin versus 2021–2022 indicates that earlier earnings economics have not been fully maintained. Continued normalization would reduce the amount of revenue converted into profit and could constrain future returns on growth investment.
Volatile Cash ConversionThe sharp cash-flow reversal followed by recovery suggests that cash conversion can vary materially between reporting periods, potentially because of working-capital timing or other operating movements. Such volatility makes liquidity planning and dependable funding of distributions or expansion more difficult.
Beijing Tong Ren Tang Chinese Medicine Co News
3613 FAQ
What was Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price range in the past 12 months?
Beijing Tong Ren Tang Chinese Medicine Co Ltd lowest stock price was HK$5.49 and its highest was HK$9.50 in the past 12 months.
What is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s market cap?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s market cap is HK$4.63B.
When is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s upcoming earnings report date?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s upcoming earnings report date is Apr 01, 2027 which is in 189 days.
How were Beijing Tong Ren Tang Chinese Medicine Co Ltd’s earnings last quarter?
Beijing Tong Ren Tang Chinese Medicine Co Ltd released its earnings results on Aug 28, 2026. The company reported HK$0.24 earnings per share for the quarter.
Is Beijing Tong Ren Tang Chinese Medicine Co Ltd overvalued?
According to Wall Street analysts Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price is currently Undervalued.
Does Beijing Tong Ren Tang Chinese Medicine Co Ltd pay dividends?
Beijing Tong Ren Tang Chinese Medicine Co Ltd pays a Notavailable dividend of HK$0.4 which represents an annual dividend yield of 6.68%. See more information on Beijing Tong Ren Tang Chinese Medicine Co Ltd dividends here
What is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s EPS estimate?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Tong Ren Tang Chinese Medicine Co Ltd have?
Beijing Tong Ren Tang Chinese Medicine Co Ltd has 837,100,000 shares outstanding.
What happened to Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price movement after its last earnings report?
Beijing Tong Ren Tang Chinese Medicine Co Ltd reported an EPS of HK$0.24 in its last earnings report. Following the earnings report the stock price went down -0.307%.
Which hedge fund is a major shareholder of Beijing Tong Ren Tang Chinese Medicine Co Ltd?
Currently, no hedge funds are holding shares in HK:3613
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beijing Tong Ren Tang Chinese Medicine Co Ltd
Beijing Tong Ren Tang Chinese Medicine Company Limited, encompassing its various affiliates, specializes in the production, distribution, and direct sale of traditional Chinese medicine and wellness items, catering to both corporate distributors and individual consumers. Its operations are geographically segmented across Hong Kong, Mainland China, and international markets. Additionally, the company provides traditional Chinese medical consultations and therapeutic services. The firm maintains a network of 23 retail stores throughout Hong Kong, complemented by 46 international outlets located across Asia, Oceania, North America, and Europe. All its offerings are sold under the well-recognized Tong Ren Tang brand. Established in 1669, the company's main office is situated in Wan Chai, Hong Kong.
3613 Stock 12 Month Forecast
Average Price Target
HK$10.50
▲(60.55% Upside)
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Tong Ren Tang Technologies Co
―
Modern Chinese Medicine Group Co. Ltd.
―
Gushengtang Holdings Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―